

Alkyl Tail Variation on Chalcone-based Quaternary Pyridinium Salts as Rule-of-Thumb for Antimicrobial Activity

Francesca Seghetti^{1§}, Riccardo Ocello^{1,2^}, Alessandra Bisi¹, Matteo Masetti¹, Silvia Gobbi¹, Federico Falchi^{1,2}, Giovanna Angela Gentilomi^{3,4}, Francesca Bonvicini^{3*}, Federica Belluti^{1*}

¹Department of Pharmacy and Biotechnology, *Alma Mater Studiorum*-University of Bologna, Via Belmeloro, 6, 40126 Bologna, Italy.

²Computational and Chemical Biology, Italian Institute of Technology IIT, via Morego 30, 16163 Genoa, Italy.

³Department of Pharmacy and Biotechnology, *Alma Mater Studiorum*-University of Bologna, Via Massarenti 9, 40138 Bologna, Italy.

⁴Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti 9, Bologna, 40138, Italy.

Present address: [§] Aptuit, an Evotec Company, Via Alessandro Fleming, 4, Verona 37135, Italy.

[^]These authors contributed equally to this work

*Corresponding authors: francesca.bonvicini4@unibo.it, Tel: +39 051 4290930; federica.belluti@unibo.it Tel: +39 051 2099701.

Contents

Figure S1.	Dose-response curves of the active chalcone-based QPySs on the tested reference strains.	S1
Figure S2.	Antibiofilm activity of the chalcone-based QPySs (4-6) on the tested reference strains.	S2
Figure S3.	Cluster Analysis of QPySs 2 and 5	S3
Figure S4.	¹ H NMR of compound 1	S5
Figure S5.	¹³ C NMR of compound 1	S5
Figure S6.	¹ H NMR of compound 2	S6
Figure S7.	¹³ C NMR of compound 2	S6
Figure S8.	¹ H NMR of compound 3	S7
Figure S9.	¹³ C NMR of compound 3	S7
Figure S10.	¹ H NMR of compound 4	S8
Figure S11.	¹³ C NMR of compound 4	S8
Figure S12.	¹ H NMR of compound 5	S9
Figure S13.	¹³ C NMR of compound 5	S9
Figure S14.	¹ H NMR of compound 6	S10
Figure S15.	¹³ C NMR of compound 6	S10
Figure S16.	¹ H NMR of compound 7	S11
Figure S17.	¹³ C NMR of compound 7	S12
Figure S18.	¹ H NMR of compound 8	S13
Figure S19.	¹³ C NMR of compound 8	S13
Figure S20.	¹ H NMR of compound 9	S14
Figure S21.	¹³ C NMR of compound 9	S14
Figure S22.	¹ H NMR of compound 10	S15
Figure S23.	¹³ C NMR of compound 10	S15
Figure S24.	¹ H NMR of compound 11	S16
Figure S25.	¹³ C NMR of compound 11	S16






Figure S1. Dose-response curves of the **active** chalcone-based QPySs on the tested reference strains. Curves are obtained by using a nonlinear regression equation and a variable slope model (log(inhibitor) vs. normalised response -- Variable slope (GraphPad Prism version 9.4.1 for Windows).




Figure S2. Antibiofilm activity of the chalcone-based QPySs (4-6) on the tested reference strains. Data are the mean percentage values of the biofilm biomass determined by CV staining of the compounds at the different concentrations relative to the untreated biofilms.





Figure S3. Cluster Analysis of QPySs 2 and 5. All dihedral angles were considered to cluster the ligands. The Gromos method was used adopting a 1.25 Å for the RMSD cut-off. QPySs structures corresponding to the three main clusters are represented for comparison. Each structure belonging to the three main clusters is also projected on the first two components obtained from a Principal Component Analysis performed considering α, β, γ dihedral angles.

NMR spectra





Figure S4. ¹H NMR spectrum (600 MHz, CDCl₃) of compound 1.







Figure S5. ¹³C NMR spectrum (150 MHz, CDCl₃) of compound 1.






Figure S8. ¹H NMR spectrum (600 MHz, DMSO-d₆) of compound 3.




Figure S9. ¹³C NMR spectrum (151 MHz, DMSO-d₆) of compound 3.




Figure S10. ¹H NMR spectrum (600 MHz, CDCl₃) of compound 4




Figure S11. ¹³C NMR spectrum (151 MHz, CDCl₃) of compound 4




Figure S12. ¹H NMR spectrum (400 MHz, CDCl₃) of compound 5.




Figure S13. ¹³C NMR spectrum (400 MHz, CDCl₃) of compound 5.




Figure S14. ¹H NMR spectrum (600 MHz, CDCl₃) of compound 6.




Figure S15. ¹³C NMR spectrum (151 MHz, CDCl₃) of compound 6.




Figure S16. ¹H NMR spectrum (600 MHz, CDCl₃) of compound 7.






Figure S17. ¹³C NMR spectrum (151 MHz, CDCl₃) of compound 7






Figure S20. ¹H NMR spectrum (400 MHz, DMSO-d₆) of compound 9




Figure S21. ¹³C NMR spectrum (151 MHz, CDCl₃) of compound 9




Figure S22. ¹H NMR spectrum (600 MHz, CDCl₃) of compound 10.




Figure S23. ¹³C NMR spectrum (151 MHz, CDCl₃) of compound 1





Figure S24. ¹H NMR (600 MHz, CDCl₃) of compound 11.




Figure S25. ¹³C NMR (151 MHz, CDCl₃) of compound **11**